Smeds MR, Duncan AA, Harlander-Locke MP, Lawrence PF, Lyden S, Fatima J et al (2016) Treatment and outcomes of aortic endograft infection. J Vasc Surg févr 63(2):332–340

Article  Google Scholar 

Bosco F, Cacciola G, Giustra F, Risitano S, Capella M, Vezza D, Barberis L, Cavaliere P, Massè A, Sabatini L (2023) Characterizing recurrent infections after one-stage revision for periprosthetic joint infection of the knee: a systematic review of the literature. Eur J Orthop Surg Traumatol 33(7):2703–2715. https://doi.org/10.1007/s00590-023-03480-7

Article  PubMed  PubMed Central  Google Scholar 

Zhang C, Liu Z, Lin Y, Cai Y, Zhang X, Huang Z et al (2022) Patient-reported outcome on quality of life and pain after revision arthroplasty for periprosthetic joint infection: A cross-sectional study. J Clin Med 11(23):7182

Article  PubMed  PubMed Central  Google Scholar 

Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis janv 56(1):e1-25

Article  Google Scholar 

Pouderoux C, Becker A, Goutelle S, Lustig S, Triffault-Fillit C, Daoud F et al (2019) Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. J Antimicrob Chemother 74(7):2060–4

Article  CAS  PubMed  Google Scholar 

Rottier W, Seidelman J, Wouthuyzen-Bakker M (2023) Antimicrobial treatment of patients with a periprosthetic joint infection: basic principles. Arthroplasty 5(1):10

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonello RM, D’Oria M, Cavallaro M, Dore F, Cova MA, Ricciardi MC et al (2019) Management of abdominal aortic prosthetic graft and endograft infections. A multidisciplinary update. J Infect Chemother 25(9):669–80

Article  PubMed  Google Scholar 

ESCMID∗ guideline for the diagnosis and treatment of biofilm infections 2014 - Clinical Microbiology and Infection [Internet]. [cité 3 mai 2023]. Disponible sur: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)00090-1/fulltext

Escudero-Sanchez R, Senneville E, Digumber M, Soriano A, Del Toro MD, Bahamonde A et al (2020) Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect avr 26(4):499–505

Article  CAS  Google Scholar 

Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH (2022) Clinical pharmacokinetics and pharmacodynamics of Dalbavancin. Clin Pharmacokinet 61(3):363–74

Article  CAS  PubMed  Google Scholar 

Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L et al (2019) Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection 47(6):1013–20

Article  CAS  PubMed  Google Scholar 

Dunne Extended-duration dosing and distribution of dalbavancin into bone and articular tissue [Internet]. [cité 5 mai 2023]. Disponible sur: https://doi.org/10.1128/AAC.04550-14

Matt M, Duran C, Courjon J, Lotte R, Moing VL, Monnin B et al (2021) Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. J Glob Antimicrob Resist juin 25:341–345

Article  CAS  Google Scholar 

Hitzenbichler F, Mohr A, Camboni D, Simon M, Salzberger B, Hanses F (2021) Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection févr 49(1):181–186

Article  CAS  Google Scholar 

Gatti M, Viale P, Cojutti PG, Zamparini E, De Paolis M, Giannella M et al (2023) A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections. Int J Antimicrob Agents mai 61(5):106773

Article  CAS  Google Scholar 

Cojutti PG, Rinaldi M, Gatti M, Tedeschi S, Viale P, Pea F (2021) Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. Int J Antimicrob Agents 58(5):106445

Article  CAS  PubMed  Google Scholar 

Simon S, Frank BJH, Hartmann S, Hinterhuber L, Reitsamer M, Aichmair A et al (2022) Dalbavancin in Gram-positive periprosthetic joint infections. J Antimicrob Chemother 77(8):2274–7

Article  CAS  PubMed  Google Scholar 

Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A et al (2019) French national cohort of first use of dalbavancin: A high proportion of off-label use. Int J Antimicrob Agents 54(5):668–72

Article  CAS  PubMed  Google Scholar 

Núñez-Núñez M, Casas-Hidalgo I, García-Fumero R, Vallejo-Rodríguez I, Anguita-Santos F, Hernández-Quero J et al (2020) Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm 27(5):310–312

Article  PubMed  Google Scholar 

Spaziante M, Franchi C, Taliani G, D’Avolio A, Pietropaolo V, Biliotti E et al (2019) Serum bactericidal activity levels monitor to guide Intravenous Dalbavancin Chronic suppressive therapy of inoperable staphylococcal prosthetic Valve Endocarditis: A case report. Open Forum Infect Dis 6(11):ofz427

Article  PubMed  PubMed Central  Google Scholar 

Howard-Anderson J, Pouch SM, Sexton ME, Mehta AK, Smith AL, Lyon GM et al (2019) Left ventricular assist device infections and the potential role for Dalbavancin: A case report. Open Forum Infect Dis 6(9):ofz235

Article  PubMed  PubMed Central  Google Scholar 

Barbero Allende JM, García Sánchez M, CulebrasLópez AM, Agudo AR (2021) Suppressive antibiotic treatment with dalbavancin. A case report. Rev Esp Quimioter 34(2):151–3

Article  CAS  PubMed  Google Scholar 

Matesanz M, Poza A, Iñurrieta A, Fernández-Diaz E, Arroyo M, Domínguez I et al (2021) Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus. Rev Esp Quimioter août 34(4):396–399

Article  CAS  Google Scholar 

Ruiz-Sancho A, Núñez-Núñez M, Castelo-Corral L, Martínez-Marcos FJ, Lois-Martínez N, Abdul-Aziz MH et al (2023) Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety. Front Pharmacol 14:1185602

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lepak A, Marchillo K, VanHecker J, Andes D (2015) Impact of glycopeptide resistance in staphylococcus aureus on the Dalbavancin In Vivo pharmacodynamic target. Antimicrob Agents Chemother déc 59(12):7833–7836

Article  CAS  Google Scholar 

Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Pérez S, López-Medrano F, San Juan-Garrido R, Ferrari-Piquero JM (2022) Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm janv 29(1):55–58

Article  Google Scholar 

Zhang R, Polenakovik H, Barreras Beltran IA, Waalkes A, Salipante SJ, Xu L et al (2022) Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a patient treated with Dalbavancin: Case report and isolate characterization. Clin Infect Dis 75(9):1641–4

Article  PubMed  PubMed Central  Google Scholar 

Werth BJ, Jain R, Hahn A, Cummings L, Weaver T, Waalkes A et al (2018) Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect avr 24(4):429.e1-429.e5

Article  CAS  Google Scholar 

Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D et al (2018) Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect 7:202

Article  PubMed  PubMed Central  Google Scholar